MIVT.OB~~Sector: Healthcare~~Industry: Medical Equipment & Supplies

[setravis]

Break of the downtrend line,
Back above the 50-day MA.

Technicals
Percentage Gainer

Last Price Quote is:
42.09%above 13-day EMA
25.45%above 50-day EMA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $43.21 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: N/A

[rdemp52572]

I'm really looking forward to the CC tomorrow - high noon!. I started at the beginning of this thread (pg 1) by accident and couldn't believe how similar last July 11th was today's action. What a fluke and hoping we take out $1 this July 11th!

[rdemp52572]

Top 5 Reasons To Watch/Own MIVT:

1. HUGE MARKET - The total cardiovascular stent market in 2005 was approximately $7 billion in 2005.

2. PRODUCT RECOGNITION - Drug/device merchandise has gained significant popularity and represents approximately 70% of the market.

3. STRATEGY ON TARGET - MIVT cites growing body of scientific evidence validating company's strategy.

4. ADVANCED STAGES OF RESEARCH - Successful pre-clinical trials completed with additional trials underway.

5. MARKET GROWTH - MIVT expands into the $1B stroke business. Positive results obtained from advanced exploratory studies on the company's stroke prevention device (AEPD) pave the way for further full-scale animal and human clinical trials and ultimately, FDA approval and commercialization.

MIV Therapeutics Updates Investors on Key Scientific Data Supporting Advantages of Company's Biocompatible Stent Technology

Company President Mark Landy to Host July 11 Conference Call to Discuss Breakthrough Data on Hydroxyapatite Safety:

http://biz.yahoo.com/bw/060711/20060711005311.html?.v=1

[rdemp52572]

Top 5 Reasons To Watch/Own MIVT:

1. HUGE MARKET - The total cardiovascular stent market in 2005 was approximately $7 billion in 2005.

2. PRODUCT RECOGNITION - Drug/device merchandise has gained significant popularity and represents approximately 70% of the market.

3. STRATEGY ON TARGET - MIVT cites growing body of scientific evidence validating company's strategy.

4. ADVANCED STAGES OF RESEARCH - Successful pre-clinical trials completed with additional trials underway.

5. MARKET GROWTH - MIVT expands into the $1B stroke business. Positive results obtained from advanced exploratory studies on the company's stroke prevention device (AEPD) pave the way for further full-scale animal and human clinical trials and ultimately, FDA approval and commercialization.

MIV Therapeutics Updates Investors on Key Scientific Data Supporting Advantages of Company's Biocompatible Stent Technology

Company President Mark Landy to Host July 11 Conference Call to Discuss Breakthrough Data on Hydroxyapatite Safety:

http://biz.yahoo.com/bw/060711/20060711005311.html?.v=1

I figured why not put it on both boards. I'm really glad I scored some shares yesterday because after this afternoon hopefully we'll have a "1" before our pennies!

[setravis]

Press Release Source: MIV Therapeutics Inc.


MIV Therapeutics Announces Company's Biocompatible Stents Matches or Outperforms World's Leading Drug-Eluting Stent in Key Categories
Wednesday November 29, 4:00 pm ET 
Excellent Results from Preclinical Study of Biocompatible Polymer-Free Drug Eluting Stent Coating Technologies Paves the Way Towards Human Trials


ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT - News; FWB:MIV), a leading developer of next-generation biocompatible polymer-free drug-eluting stents and advanced drug delivery systems, announced today that a comparative animal study of two of its novel polymer-free drug-eluting stent coating technologies has concluded with positive results.
ADVERTISEMENT



This study compared stents coated with MIVT's polymer-free drug-eluting technologies to the J&J Cypher(TM) stent, one of the world's best selling drug-eluting stents. The Study successfully demonstrated that both of MIVT's proprietary, polymer-free, Sirolimus eluting coatings are at least as good as Johnson & Johnson's Cypher(TM) Stent. The study also demonstrated MIVT's coatings' potential and efficacy when compared to Cypher(TM).

The independently conducted four-week porcine study, performed by the Department of Cardiology, Thoraxcenter, Erasmus University Medical Center in the Netherlands, indicated that three variations of MIV's polymer-free Drug-Eluting coatings were at least as effective as -- and in some cases, better -- than Johnson & Johnson's Cypher, one of the world's leading drug-eluting cardiovascular stents.

Dr Willem J. van der Giessen, MD, PhD, Interventional Cardiologist and Dr. Heleen M.M van Beusekom, PhD, Experimental Cardiology, from the Thoraxcenter at the Erasmus University Medical Center were the study directors. The objectives of the study were to evaluate the safety of MIVT's Hydroxyapatite coating and to assess the efficacy of MIVT Sirolimus coated stents in a porcine coronary model.

The results from the first part of the study, conducted with no drug added to the coatings, showed that HAp coated stents and bare metal stents did best and performed equally well.

The results from the second part of the study, with drugs added to the coatings, showed that all of the MIVT drug-eluting technologies performed at least as well, and in some cases better than the industry's benchmark, the J&J Cypher(TM) stent.

The study concluded that MIV's HAp coating, with or without drugs, demonstrated highly promising performance. Based on these results the company will begin preparations for human implantation.

"The results of this study indicate that our drug-eluting polymer-free technologies are at least on par with the best in the world. We believe we have very strong candidates for a superior product as we move into the next phase of our regulatory program," said Dr. Mark Landy, President of MIV Therapeutics.

The study was conducted in a standard model of porcine coronary arteries and utilized angiography and histology to evaluate tissue response to stents coated with MIVT's proprietary polymer-free coatings in comparison to identical bare metal stents and also stents coated with MIVT's proprietary Sirolimus eluting technology to J&J's Cypher(TM) (Sirolimus) stent.

MIV Therapeutics is developing a diverse suite of Polymer-Free HAp coating formulas to improve the biocompatibility of stents and other implantable medical devices. Hydroxyapatite (HAp) occurs naturally in human bones and teeth. It rapidly integrates into the human body and has been shown to have excellent stability and biocompatibility. HAp is non-toxic, non-thrombogenic, non-inflammatory and has been shown to promote angiogenesis.

HAp coatings are also expected to reduce the increased risk of deadly blood clots currently associated with today's polymeric drug-eluting stents. Recent information presented at leading cardiology conferences estimated that blood clots have been identified in at least 20,000 cases of implanted drug-eluting stents to-date, resulting in approximately 8,000 premature deaths.

MIVT recently announced that it intends to begin the first human implants of a HAp Nano Film Coated stent early in 2007. Human implantation represents a significant milestone in MIVT's strategic plan to develop a new class of polymer-free drug-eluting stents that could provide patients with superior outcomes.

About MIV Therapeutics, Inc.

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug-eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug-eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug-eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.



Contact:
MIV Therapeutics Inc.
Investor Relations
Denis Corin, 604-301-9545 x14
Toll-free: 800-221-5108
Fax: 604-301-9546
[email protected]
http://www.mivtherapeutics.com/
or
Trilogy Capital Partners
Paul Karon, Toll-free: 800-592-6067
[email protected]

--------------------------------------------------------------------------------
Source: MIV Therapeutics Inc.

[setravis]

"MIVT.OB" Threads have been Merged.
Please use the search before starting new threads on a Stock Pick.
Chances are a thread already exist.
So why not post whatever you have to comment about on that pick to that thread.
"Simplicity" My fellow traders.       
All history on a stock pick in 1 thread is awesome.     

Thank You....and good luck with all your trades....make some $$$

[setravis]

Hello, anyone with me here ? 
Reversal in the making here.......and by the way check out BPA....

52wk Range: 0.35 - 1.45
Volume: 408,585
Avg Vol (3m): 168,178

Technicals
Percentage Gainer

Last Price Quote is:
28.83%above 13-day MA
23.37%above 50-day MA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $42.18 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: N/A

[setravis]

 


Press Release Source: MIV Therapeutics, Inc.


MIV Therapeutics 'Buy/4' Rating, $2.50 Target Valuation Reiterated In Research Note By Investrend Affiliate SISM Research, Indicating Greater Market Potential And Citing Recent Superior Performance of Stent Coating Technologies In Recent Tests
Friday December 8, 8:30 am ET 
MIVT's Biocompatible Polymer-Free Drug-Eluting Stent Coating Technologies Shown in Tests to be Better Than the Industry's Benchmark Cypher Stent, One of the World's Best Selling Drug-Eluting Stents


NEW YORK--(BUSINESS WIRE)--(Investrend Research Syndicate) Ernest C. Schlotter, a senior analyst with Investrend affiliate SISM Research and a four star analyst according to StarMine, has reiterated his "Buy/4" Rating and $2.50 12-month Target Valuation for MIV Therapeutics, Inc. (OTCBB: MIVT - News) in a Research Note.


The full Research Note, including important disclosures and disclaimers, is available at http://www.sism.com and http://www.investrendresearch.com. In it, analyst Schlotter said:

"Just last Wednesday, MIVT announced remarkable results from preclinical studies of two of its novel biocompatible polymer-free drug-eluting stent coating technologies that matched or even outperformed Cordis' and Boston Scientific's drug eluting stents. The independently conducted four-week porcine study at the Erasmus University Medical Center in the Netherlands compared stents coated with MIVT's polymer-free drug-eluting technologies to the industry's benchmark, the J&J Cypher stent, one of the world's best selling drug-eluting stents. Three variations of MIVT's polymer-free Sirolimus eluting coatings were at least as effective as -- and in some cases, better -- than Johnson & Johnson's Cypher drug-eluting cardiovascular stents. Based on these results, MIVT will begin preparations for human implantation.

"MIV Therapeutics is developing a diverse suite of polymer-free HAp coating formulas...

"The drug-eluting stent market grew from zero to $5.3 billion in three years and has captured 85% of the US stent market. To date, more than nine million DES devices have been inserted. In 2005, about 1.5 million patients were implanted with drug-eluting stents in the US alone...

"Despite a stock price increase of more than 50% since last Wednesday, in our view, MIVT, at a market cap of only $35 million, is still massively undervalued... MIV Therapeutics is paying SISM Research $2,250 per month over a two-year period solely to ensure independent coverage."

SISM Research, based in Zurich, Switzerland, is a private investment research firm offering high-quality, independent, fundamental research on public companies since 1995. SISM writes, publishes and distributes research coverage on micro- to small-cap public companies trading on the OTC, NASDAQ and AMEX.

This coverage is geared toward institutional and individual investors in both North America and in German-speaking Europe, a market that represents more than 100 million people. SISM Research is a content provider to Thomson Financials OneAnalytics/FirstCall and Investext, to Reuters Multex, and Investrend.

The full report, including important disclosures and disclaimers, is available at http://www.sism.com, http://www.investrendresearch.com, and at the company's InvestorPower Page accessible from http://www.investrend.com/company/list.asp?sPathParam=yes. Investors are advised to read those disclosures carefully before trading in the equities of any enrolled company.

Both SISM Research and Investrend Research subscribe to the "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com, and MIVT's research will be enrolled for investor monitoring by the not-for-profit Shareholders Research Alliance, Inc. (http://www.shareholdersresearch.com).

Anyone interested in receiving alerts regarding MIV Therapeutics research should email [email protected] with "MIVT" in the subject line.

Contact:
MIV Therapeutics, Inc.
Investor Relations
604-301-9545 x14
Toll-free: 800-221-5108
http://www.mivtherapeutics.com/
or
Investrend Research Div.
Investrend Communications, Inc.
R. Hempel, 718-896-5060
[email protected]
www.investrendresearch.com

--------------------------------------------------------------------------------
Source: MIV Therapeutics, Inc.

[gmarc66]

Hey Setravis..i just noticed we posted at almost the same time..so im modifying my post..lol.


Any thoughts on this chart Setravis?

Setravis..you are doing a great job with the merging of the threads!!! I'm sure its a nightmare..i can see u have been very busy...great work..thanks a bunch, u r saving us alot of hassle And, looks like u did this one just in time for me..lol
Friday, December 08 2006 8:30 AM, EST


Thanks!!!!

julia

[setravis]

Hey Setravis..i just noticed we posted at almost the same time..so im modifying my post..lol.


Any thoughts on this chart Setravis?

Setravis..you are doing a great job with the merging of the threads!!! I'm sure its a nightmare..i can see u have been very busy...great work..thanks a bunch, u r saving us alot of hassle And, looks like u did this one just in time for me..lol
Friday, December 08 2006 8:30 AM, EST


Thanks!!!!

julia

Hi Julia,
Did you not see my post above yours here ?
Yes, it is a job getting these threads merged, ah but it is so much better for everyone to post their
comments or whatever on one thread. The History of the stock pick all in one place....without having to search all over hell !    I just can't make some understand my point on this.

#1 There you have when the pick was made. 

#2 What did the stock do... 

#3 Move up 

#4 Move down 

#5 Move sideways for a time 

#6 If we had a run, when did she start to fall ?   

#7 "Simplicity" There you have all the history on a pick at the click of your mouse!!
       Why would one want to search a dozen different threads for info....Beats the hell out of me 

Have a great weekend Julia.......make some dough $ !!!
Best Regards,

[setravis]

Press Release Source: MIV Therapeutics Inc.


MIV Therapeutics Executes Milestone Agreement to Acquire Biosync Scientific, a Leading Indian Interventional Cardiology Company
Monday December 11, 3:30 am ET 
Acquisition Provides MIVT with Highly Competitive CE Marked Bare Metal Stent Platform


ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB: MIVT - News; FWB: MIV), a leading developer of next-generation biocompatible polymer-free drug-eluting stents and advanced drug delivery systems, announced that it has entered into a formal agreement to acquire Biosync Scientific, an India-based designer and developer of innovative interventional cardiology products, including cardiovascular stents.


Biosync Scientific provides MIVT with a highly competitive bare metal stent platform that compares favorably with the best bare metal stents available today. Both Biosync's stainless steel and thin-strut cobalt chromium stent platforms are CE Mark-certified for use in Europe and other countries around the world where the CE Mark is recognized such as India. MIVT will use the Biosync stent platform as the underlying bare-metal stent platform for its proprietary biocompatible polymer-free next generation drug-eluting stents.

The Biosync Scientific acquisition which is subject to the prior satisfaction of certain conditions, is the latest step in MIVT's strategic plan to become a world leader in the $8 billion plus interventional cardiology market. In September, MIVT entered into a formal agreement to acquire Vascore Medical, a China-based manufacturer and distributor of advanced interventional cardiology devices.

Biosync Scientific was founded by Rajesh Vaishnav, a well known and highly respected authority in the Indian Interventional Cardiology Industry. Over the past decade Mr. Vaishnav has been responsible for developing many of the leading bare-metal and drug-eluting stents currently being sold in India and other emerging markets around the world. Mr. Vaishnav will join MIVT as Chief Executive Officer of Biosync Scientific.

"The acquisition of Biosync Scientific brings us not only a highly competitive CE Mark stent platform for our revolutionary polymer-free drug-eluting coatings, but also the expertise and experience of Mr. Vaishnav, one of India's most respected and well known stent authorities," said Dr. Mark Landy, President of MIV Therapeutics. "It is an honor to welcome Mr. Vaishnav and his team to the MIVT family, and we look forward to working together with them as we continue to build our brand around the world."

Biosync Scientific's stated mission is to improve the quality of patient care and the productivity of health care delivery through the development and advocacy of less-invasive medical devices and procedures. This is accomplished through the continuing refinement of existing products and procedures and the investigation and development of new technologies which can reduce risk, trauma, cost, procedure time and the need for aftercare.

About MIV Therapeutics, Inc.

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug-eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug-eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug-eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.


Contact:
MIV Therapeutics Inc.
Denis Corin, 604-301-9545 ext. 14 (Investor Relations)
Toll-free: 800-221-5108
Fax: 604-301-9546
[email protected]
http://www.mivtherapeutics.com/
or
Trilogy Capital Partners
Paul Karon, Toll-free: 800-592-6067
[email protected]

--------------------------------------------------------------------------------
Source: MIV Therapeutics Inc.

[setravis]

Nice surge in volume .....
Moved her right on through the 200-day MA.

52wk Range: 0.35 - 1.45
Volume: 1,232,695
Avg Vol (3m): 173,838

Technicals
Percentage Gainer

Last Price Quote is:
65.68%above 13-day MA
63.69%above 50-day MA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $42.18 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: N/A

[setravis]

Form 8-K for MIV THERAPEUTICS INC


--------------------------------------------------------------------------------

12-Dec-2006

Other Events



Item 8.01 Other Events.
Effective on October 16, 2006, and again on November 8, 2006, the Company recently ratified and completed a private placement (the "Private Placement") with certain non-United States residents (each an "Investor") for aggregate proceeds of $1,000,000.00 pursuant to the terms and conditions of certain unit private placement subscription agreements (collectively, the "Subscription Agreements") as entered into between the Company and each such Investor.

In accordance with the terms of the Subscription Agreements: (a) the Company issued an aggregate of 2,000,000 units of the Company (each a "Unit"), at a subscription price of $0.50 per Unit; (b) each Unit is comprised of one share of the Company's restricted common stock, par value $0.001 (each a "Share" and, collectively, the Company's "Common Stock"), and one non-transferable common share purchase warrant (each a "Warrant"); (c) each Warrant entitles the Investor to purchase an additional share of the Company's Common Stock (each a "Warrant Share") commencing upon the date of issuance of the underlying Units and ending on the day which is 24 months from the date of issuance of the Units; and (d) the exercise price of the Warrants is $0.75 per Warrant Share during the entire Warrant exercise period.

In conjunction with the completion of the Private Placement, the Company has agreed to issue finders' fees comprised of: (i) cash fees in the aggregate of $100,000; and (ii) an aggregate of 100,000 Private Placement Units of the Company.

The Company has also agreed to file a registration statement with the United States Securities and Exchange Commission covering the resale of the Shares and the Warrant Shares issuable upon the exercise of the Warrants.

The Private Placement was made and sold only to non-United States Investors in reliance on Regulation S promulgated under the United States Securities Act of 1933, as amended (the "Act"). The Private Placement has not been registered under the Act or under any state securities laws and may not be offered or sold without registration with the United States Securities and Exchange Commission or an applicable exemption from the registration requirements.

SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS

*****************************************************

Falling Wedge (reversal) Pattern.

[setravis]

An setravis....hoorah ! 

Now @ +31.65%.......Volume @ 2,029,409.......

[setravis]

Press Release Source: MIV Therapeutics Inc.


MIV Therapeutics Announces Market Launch of the GenX CrCo Stent and Seven Associated Interventional Cardiology Products by Biosync Scientific
Thursday December 14, 3:30 am ET 
Launch is a Key Milestone in the Company's Mission to Deliver a Broad Range of Products to the Interventional Cardiology Community


ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT - News; FWB:MIV), a leading developer of next-generation biocompatible polymer-free drug-eluting stents and advanced drug delivery systems, has announced that Biosync Scientific, which the Company has a formal agreement to acquire, has introduced a portfolio of new cardiovascular stents and related products at the 58th Annual Meeting of The Cardiological Society (CSI) of India, held recently in New Delhi.


The seven newly announced products validate MIVT's mission to become a leading interventional cardiology company focused on delivering a broad suite of advanced cardiovascular stents and related products to patients, physicians and hospitals around the world.

The new products include the GenX CrCo thin-strut coronary stent system, the GenX stainless steel coronary stent system, the X-ACT Inflation Device, a haemostatic y-connector adaptor kit, an insertion tool, a guide wire torquer and a high-pressure 3-way stopcock.

Notably, the products have all been CE Mark certified, a mandatory European community stamp of approval that enables products to be sold in Europe and other key markets around the world.

MIVT and Biosync will roll out these products over the next quarter, under a strategic plan that will deliver them first to the interventional cardiology community in India, to be followed with distribution in other countries in Asia, Europe, Latin America and elsewhere.

The products allow MIVT to accelerate the development of its brand and distributor relationships around the world as the Company prepares for the commercialization of its broad range of hydroxyapatite (HAp) coated stents, polymer-free drug-eluting stents, and other interventional cardiology products.

"This launch is an important milestone in the transformation of MIV Therapeutics into a full-fledged interventional cardiology company with a broad product portfolio and deep product pipeline," said Dr. Mark Landy, President of MIV Therapeutics. "Given the exceptional response from CSI members, we believe that these products will become instrumental in the treatment of coronary heart disease around the world for many years to come."

Dr. Landy added, "The launch of these products provides MIVT an opportunity to develop strong relations with established distribution networks around the world as we prepare the market for the roll out our HAp-coated and polymer-free biocompatible drug-eluting stents and other associated interventional cardiology products."

The recently announced proposed Biosync Scientific acquisition is the latest step in MIVT's strategic plan to become a world leader in the $8 billion plus interventional cardiology market.

About MIV Therapeutics, Inc.

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug-eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug-eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug-eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.


Contact:
MIV Therapeutics Inc.
Investor Relations
Denis Corin, 604-301-9545 x14
Toll-free: 800-221-5108
Fax: 604-301-9546
[email protected]
http://www.mivtherapeutics.com/
or
Trilogy Capital Partners
Paul Karon, Toll-free: 800-592-6067
[email protected]

--------------------------------------------------------------------------------
Source: MIV Therapeutics Inc.